What Researchers Did
Researchers pooled data from 30 randomized controlled trials (2,075 patients total) to compare HBOT alone versus HBOT plus edaravone (a free-radical scavenger drug) for treating the brain damage that sometimes develops weeks after carbon monoxide poisoning.
What They Found
Adding edaravone to HBOT increased overall treatment success rates by 25% (RR: 1.25). Cognitive test scores improved significantly (MMSE +3.67 points, MoCA +4.38 points), daily function scores improved (Barthel Index +10.94 points), and neurological damage scores decreased (NIHSS -4.12 points). Antioxidant markers also improved with the combination.
What This Means for Canadian Patients
For Canadians who survive acute carbon monoxide poisoning but then develop cognitive decline weeks later — a condition called delayed encephalopathy — HBOT is already a recognized treatment. This evidence suggests adding edaravone could produce better cognitive and functional recovery, though edaravone is not yet widely available in Canada.
Canadian Relevance
Carbon monoxide poisoning is an OHIP-covered indication for HBOT in Ontario. The combination therapy evidence is relevant, though edaravone's Canadian availability is limited.
Study Limitations
The evidence quality is rated low, most studies are Chinese, and edaravone is not standard care in Canada or most Western countries.